MMLV, with higher processivity

  • Discontinued Patent

In the Public Domain since

13 Nov 2018

Description

Methods for expressing recombinant Moloney Murine Leukemia Virus (MMLV) reverse transcriptase

Abstract

This invention provides recombinant murine leukemia virus reverse transcriptases, genes encoding these proteins and expression methods. The said murine leukemia virus reverse transcriptases are a series of MLV-RT proteins wherein the 84th amino acid residue (Q84) from the N-terminus is replaced with amino acid X, which is an amino acid with a side chain shorter than glutamine. The said murine leukemia virus reverse transcriptases have higher enzyme activity and processivity than the wild type enzyme, and are expected to be widely used in the field of biotechnology for cDNA synthesis.

Category

Others > COVID-19, Enzymes > Reverse Transcriptases

Related Inventors

unknown

Source

US Patent No 7,794,996

Patent Title: Recombinant murine leukemia virus reverse transcriptases, the genes encoding and the method for expressing it

View on Lens

DNA sequence(s) on Lens

Patent family on Lens